These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 34077785)

  • 1. Endocrine resistance and epigenetic reprogramming in estrogen receptor positive breast cancer.
    Dimitrakopoulos FI; Kottorou A; Tzezou A
    Cancer Lett; 2021 Oct; 517():55-65. PubMed ID: 34077785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response.
    Pathiraja TN; Stearns V; Oesterreich S
    J Mammary Gland Biol Neoplasia; 2010 Mar; 15(1):35-47. PubMed ID: 20101445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic mechanisms of cancer progression and therapy resistance in estrogen-receptor (ER+) breast cancer.
    Toska E
    Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189097. PubMed ID: 38518961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Mechanisms of Endocrine Resistance in Estrogen-Positive Breast Cancer.
    Belachew EB; Sewasew DT
    Front Endocrinol (Lausanne); 2021; 12():599586. PubMed ID: 33841325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer epigenetics: a perspective on the role of DNA methylation in acquired endocrine resistance.
    Trimarchi MP; Mouangsavanh M; Huang TH
    Chin J Cancer; 2011 Nov; 30(11):749-56. PubMed ID: 22035855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic regulation of estrogen signaling in breast cancer.
    Hervouet E; Cartron PF; Jouvenot M; Delage-Mourroux R
    Epigenetics; 2013 Mar; 8(3):237-45. PubMed ID: 23364277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting resistance to endocrine therapy in breast cancer: It's time for epigenetic biomarkers (Review).
    Fontes-Sousa M; Amorim M; Salta S; Palma De Sousa S; Henrique R; Jerónimo C
    Oncol Rep; 2019 Mar; 41(3):1431-1438. PubMed ID: 30664168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of endocrine therapy resistance in breast cancer.
    Rasha F; Sharma M; Pruitt K
    Mol Cell Endocrinol; 2021 Jul; 532():111322. PubMed ID: 34000350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanisms.
    Bianco S; Gévry N
    Transcription; 2012; 3(4):165-70. PubMed ID: 22771991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXO factors and breast cancer: outfoxing endocrine resistance.
    Bullock M
    Endocr Relat Cancer; 2016 Feb; 23(2):R113-30. PubMed ID: 26612860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine Resistance in Breast Cancer: The Role of Estrogen Receptor Stability.
    Jeffreys SA; Powter B; Balakrishnar B; Mok K; Soon P; Franken A; Neubauer H; de Souza P; Becker TM
    Cells; 2020 Sep; 9(9):. PubMed ID: 32932819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of epigenetic modifications in luminal breast cancer.
    Abdel-Hafiz HA; Horwitz KB
    Epigenomics; 2015 Aug; 7(5):847-62. PubMed ID: 25689414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming endocrine resistance in hormone receptor-positive breast cancer.
    AlFakeeh A; Brezden-Masley C
    Curr Oncol; 2018 Jun; 25(Suppl 1):S18-S27. PubMed ID: 29910644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetics of estrogen receptor-negative primary breast cancer.
    Huynh KT; Chong KK; Greenberg ES; Hoon DS
    Expert Rev Mol Diagn; 2012 May; 12(4):371-82. PubMed ID: 22616702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic reprogramming in breast cancer: from new targets to new therapies.
    Katz TA; Huang Y; Davidson NE; Jankowitz RC
    Ann Med; 2014 Sep; 46(6):397-408. PubMed ID: 25058177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Changes During Breast Cancer and Mechanisms of Endocrine Therapy Resistance.
    Radhi S
    Prog Mol Biol Transl Sci; 2016; 144():539-562. PubMed ID: 27865467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.
    Brufsky AM; Dickler MN
    Oncologist; 2018 May; 23(5):528-539. PubMed ID: 29352052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNAs and Epigenetics Strategies to Reverse Breast Cancer.
    Rahman MM; Brane AC; Tollefsbol TO
    Cells; 2019 Oct; 8(10):. PubMed ID: 31597272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of Endocrine Resistance in Hormone Receptor-Positive Breast Cancer.
    Marra A; Trapani D; Ferraro E; Curigliano G
    Cancer Treat Res; 2023; 188():219-235. PubMed ID: 38175348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.